Bicara Therapeutics (NASDAQ:BCAX) Releases Earnings Results, Meets Expectations

Bicara Therapeutics (NASDAQ:BCAX) announced its quarterly earnings data on Tuesday. The company reported ($0.82) EPS for the quarter, meeting analysts’ consensus estimates of ($0.82), Zacks reports.

Here are the key takeaways from Bicara Therapeutics’ conference call:

• Management highlighted three-year follow-up data for FICERA in HPV-negative head and neck cancer, saying approximately one in three patients remained alive at three years—nearly double retrospective standard-of-care estimates—while maintaining a consistent safety profile.
• The pivotal FORTIFI-HN01 study remains on track for substantial enrollment by year-end, with more than 200 sites active and a planned interim analysis in mid-2027 that could support a potential accelerated approval.
• Bicara initiated the FORTIFI-FLEX study to evaluate loading and every-three-week maintenance dosing, aiming to have data available by a potential U.S. approval and support inclusion of a more convenient regimen in the product label.
• The company reported approximately $497 million in cash and marketable securities at quarter-end, providing projected runway into the first half of 2029, while warning that operating expenses will rise as pivotal-trial, manufacturing, medical-affairs, and commercial-launch investments increase.
• Leadership transitions will take effect as Ryan Cohlhepp becomes CEO and Claire Mazumdar moves to vice chair and strategic advisor; Bicara also announced new finance, operations, business, and legal leadership intended to support potential commercialization.

Bicara Therapeutics Price Performance

BCAX traded up $1.15 on Wednesday, hitting $24.91. The company had a trading volume of 136,982 shares, compared to its average volume of 603,872. Bicara Therapeutics has a 1-year low of $10.30 and a 1-year high of $30.99. The company’s fifty day moving average price is $25.90 and its 200 day moving average price is $21.69. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -8.96 and a beta of -0.75.

Analysts Set New Price Targets

BCAX has been the topic of a number of recent analyst reports. Wells Fargo & Company boosted their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Mizuho increased their price target on Bicara Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a research report on Wednesday. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Bicara Therapeutics in a research note on Wednesday. BTIG Research boosted their price objective on Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Guggenheim assumed coverage on shares of Bicara Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $42.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $32.73.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Clinical progress supports the stock: Bicara said enrollment in its pivotal cancer trial is advancing and remains on track for 2026 completion, reducing a key development-timeline risk. Wedbush also highlighted the program’s progress. Bicara Therapeutics stock gains 3% as pivotal trial enrollment advances Bicara Therapeutics’ Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: Quarterly results exceeded expectations on the bottom line: Bicara reported a second-quarter loss of $0.82 per share, matching consensus estimates and described by analysts as narrower than expected. The earnings update reinforced confidence in the company’s execution. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: BTIG became more bullish: The firm raised its price target from $28 to $39 and maintained a “buy” rating, implying substantial upside from the stock’s recent trading level. The revision provides a positive catalyst for investor sentiment. Benzinga analyst-rating report
• Neutral Sentiment: Leadership changes add an execution focus: Bicara announced strategic leadership transitions as it enters its next phase of development and growth. The changes could improve execution, but they also introduce a transition risk that investors will monitor. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Analyst views remain mixed: Wells Fargo raised its target from $16 to $23 but retained an “equal weight” rating; its new target remains below the stock’s recent level, signaling valuation concerns despite the increase. Wells Fargo price-target update

Insider Activity

In other news, COO Ryan Cohlhepp sold 28,214 shares of the business’s stock in a transaction on Wednesday, July 8th. The shares were sold at an average price of $28.98, for a total value of $817,641.72. Following the completion of the sale, the chief operating officer directly owned 182,177 shares in the company, valued at approximately $5,279,489.46. The trade was a 13.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Ivan Hyep sold 28,000 shares of the company’s stock in a transaction on Wednesday, July 8th. The stock was sold at an average price of $28.85, for a total transaction of $807,800.00. Following the sale, the chief financial officer directly owned 129,855 shares of the company’s stock, valued at approximately $3,746,316.75. This represents a 17.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 88,450 shares of company stock valued at $2,366,675 over the last 90 days. 13.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Bicara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Graham Capital Management L.P. acquired a new position in shares of Bicara Therapeutics during the fourth quarter worth approximately $221,000. Creative Planning bought a new stake in shares of Bicara Therapeutics in the third quarter valued at approximately $159,000. Orion Porfolio Solutions LLC acquired a new stake in shares of Bicara Therapeutics in the third quarter worth $178,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Bicara Therapeutics by 64.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,729 shares of the company’s stock worth $174,000 after acquiring an additional 7,354 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in Bicara Therapeutics during the second quarter worth $226,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.